NK cells complexed with bispecific antibody yield high response rates in patients with lymphoma
HOUSTON ― A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study from Â鶹ӳ» MD Anderson Cancer Center.
Results from the Phase I trial, published today in Nature Medicine, demonstrated an overall...
